MAY 30, 2016 09:53 AM PDT

Brain Cancer Survival Tied to 8 Immunity Genes

WRITTEN BY: Xuan Pham
A group of immune-related genes could predict survival for patients battling with a brain cancer type known as glioblastoma multiforme (GBM). The research identified 8 genes that seemed to modulate the prognosis of the disease. Researchers think knowing this genetic profile could guide doctors in making more informed treatment for their GMB patients.
 
Researchers identify immune genes tied to common, deadly brain cancer
Glioblastoma (GBM) is the most common and deadly form of primary brain cancer. In GBM, malignant glial cells form vast networks of tendrils throughout the brain, making it nearly impossible to surgically remove all the cancerous tissues. Dubbed as the “octopus tumor,” GBMs can evade even the most aggressive surgeries, chemotherapies, and radiotherapies, leaving patients with a five-year survival rate of less than 10%.
 

“We’ve had luck with other types of cancer in removing the brakes on the immune system to allow it to fight the tumors, but this has not been the case with glioblastoma,” said Anhua Wu, professor at the First Hospital of China Medical University in Shenyang, China, and senior study author. “If our discovery of these genes is validated in other studies, we could use this ‘gene signature’ to determine the best treatments or path of treatment.”
 
In the quest to identify the gene(s) involved with GBM survival, the team analyzed tumor samples fro 297patients with brain cancer. The patients were separated into those with low-grade glioma (170) and those with high-grade glioblastoma (127). Using genome sequencing, they found 322 genes that were related to the immune system. Of this, eight seemed to influence survival outcome. The eight genes were: FOXO3, IL6, IL10, ZBTB16, CCL18, AIMP1, FCGR2B, and MMP9.
 
From the list of eight genes, the team developed a signature profile that could classify patients as high- or low-risk. High-risk patients survived, on average, 348 days after diagnosis. This 145 days less than the low-risk patients, who survived an average of 493 days after diagnosis.
 
The same eight-gene signature was also validated in a larger sample of 536 glioblastoma samples. In addition, the prognostic value of these eight genes could also be extended to other forms of gliomas.
 
“The looming question in brain cancer research today is whether the launch of immunotherapy will help control an uncontrollable disease,” said Rifaat Bashir, a retired neurologist in Virginia and a Fellow of the American Academy of Neurology and the American Neurological Association. Bashir wrote an accompanying editorial, in which he stated: “While this study does not answer this question, it brings us one step closer to believing that one day we will be able to exploit the immune system to better treat glioblastoma.”

Additional source: American Academy of Neurology press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 17, 2018
Cell & Molecular Biology
JUL 17, 2018
A New Player in the Control of Cell Division
Oil and water don't mix; cells can take advantage of that phenomenon, phase separation, to organize stuff without using membranes...
AUG 07, 2018
Cancer
AUG 07, 2018
Is There a Best Time of Day to Administer Chemo?
A common hematologic cancer chemotherapy agent is looked at for its efficacy on solid tumors and specifically evaluates if delivery time during the day affects is anti-tumor activity....
AUG 07, 2018
Cancer
AUG 07, 2018
Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
DNA methylation patterns in renal cell carcinoma (RCC) have a strong association with myelodysplastic syndrome DNA hypermethylation later in life....
OCT 05, 2018
Cancer
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
NOV 20, 2018
Cell & Molecular Biology
NOV 20, 2018
A Warning About Using Epigenetic Modifiers as Therapeutic Targets
In the long run, some cancer therapeutics may be doing more harm than good....
Loading Comments...